These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 76932)

  • 1. Induction of remission in hepatocellular carcinoma with doxorubicin.
    Johnson PJ; Williams R; Thomas H; Sherlock S; Murray-Lyon IM
    Lancet; 1978 May; 1(8072):1006-9. PubMed ID: 76932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma in Italy: report of a clinical trial with intravenous doxorubicin.
    Colombo M; Tommasini MA; Del Ninno E; Rumi MG; De Fazio C; Dioguardi ML
    Liver; 1985 Dec; 5(6):336-41. PubMed ID: 2418328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.
    Sciarrino E; Simonetti RG; Le Moli S; Pagliaro L
    Cancer; 1985 Dec; 56(12):2751-5. PubMed ID: 2413981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin.
    Kalayci C; Johnson PJ; Raby N; Metivier EM; Williams R
    J Hepatol; 1990 Nov; 11(3):349-53. PubMed ID: 1705275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.
    Rizzi PM; Ryder SD; Ramage JK; Gane E; Karani J; Heaton N; Portmann B; Tan KC; Williams R
    Transplant Proc; 1994 Dec; 26(6):3568-9. PubMed ID: 7527979
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication.
    Olweny CL; Toya T; Katongole-Mbidde E; Mugerwa J; Kyalwazi SK; Cohen H
    Cancer; 1975 Oct; 36(4):1250-7. PubMed ID: 169983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin.
    Melia WM; Johnson PJ; Williams R
    Cancer; 1983 Jan; 51(2):206-10. PubMed ID: 6295596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
    Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
    Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Leung TW; Patt YZ; Lau WY; Ho SK; Yu SC; Chan AT; Mok TS; Yeo W; Liew CT; Leung NW; Tang AM; Johnson PJ
    Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival.
    Ihde DC; Matthews MJ; Makuch RW; McIntire KR; Eddy JL; Seeff LB
    Am J Med; 1985 Mar; 78(3):399-406. PubMed ID: 2579551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
    Abrams RA; Pajak TF; Haulk TL; Flam M; Asbell SO
    Cancer J Sci Am; 1998; 4(3):178-84. PubMed ID: 9612600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.
    Dettmer A; Kirchhoff TD; Gebel M; Zender L; Malek NP; Panning B; Chavan A; Rosenthal H; Kubicka S; Krusche S; Merkesdal S; Galanski M; Manns MP; Bleck JS
    World J Gastroenterol; 2006 Jun; 12(23):3707-15. PubMed ID: 16773687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.
    Schmidinger M; Wenzel C; Locker GJ; Muehlbacher F; Steininger R; Gnant M; Crevenna R; Budinsky AC
    Br J Cancer; 2001 Dec; 85(12):1850-2. PubMed ID: 11747325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour markers in the diagnosis and management of patients with hepatocellular carcinoma.
    Johnson PJ
    Recent Results Cancer Res; 1986; 100():68-72. PubMed ID: 2426745
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States.
    Vogel CL; Bayley AC; Brooker RJ; Anthony PP; Ziegler JL
    Cancer; 1977 May; 39(5):1923-9. PubMed ID: 66974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ferritin in hepatocellular carcinoma. A comparison with alphafetoprotein.
    Melia WM; Bullock S; Johnson PJ; Williams R
    Cancer; 1983 Jun; 51(11):2112-5. PubMed ID: 6188526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation].
    Barbare JC; Ballet F; Petit J; Poupon R; Darnis F
    Bull Cancer; 1984; 71(5):442-5. PubMed ID: 6084528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma.
    Melia WM; Johnson PJ; Williams R
    Cancer Treat Rep; 1987 Dec; 71(12):1213-6. PubMed ID: 2446752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma.
    Melia WM; Westaby D; Williams R
    Clin Oncol; 1981 Dec; 7(4):275-80. PubMed ID: 6172230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.